M88 app advises Grifols in the sale of a 20% equity stake in SRAAS and its strategic alliance with Haier Group and SRAAS
2024.06.25
On June 18, 2024, Grifols, S.A. ("Grifols"), a global healthcare company and a leading producer of plasma-derived medicines, announced completion of M88 app sale of a 20% equity stake in Shanghai RAAS (“SRAAS”) to Haier Group Corporation (“Haier Group”) for RMB 12.5 billion (approximately USD 1.8 billion). Grifols retains a 6.58% equity stake in SRAAS while forging a strategic alliance with Haier Group and SRAAS. For more information please visit:Grifols completes sale of a 20% equity stake in SRAAS M88 app forges strategic alliance with Haier Group
M88 app and Osborne Clarke Spain together served as legal counsel for Grifols in this transaction. In 2019, the two firms advised Grifols on its acquisition of a 26.2% stake in SRAAS by contributing its non-majority share in its US subsidiary Grifols Diagnostic Solutions Inc. That transaction was recognized as the Deal of the Year 2020 by China Business Law Journal.
On the M88 app side, the transaction was led by partnersM88 Malaysia 于君合上海分所执业。M88 appm88 live casino 北京绿化基金会与君合共同发起的“北京绿化基金会碳中和专项基金”M88 app assisted by, m88 live casino 许律师在处理各种复杂的跨境并购交易上具有极为丰富的经?, m88 live casino 北京绿化基金会碳中和专项基金”and DONG, Zhe. On M88 app Osborne Clarke Spain side, M88 app transaction was led by partners Tomás Dagá, Oscar Calsamiglia and José Ramón Medina and assisted by Laura de la Cruz, María Montehermoso and Marian Aleu.
